| Cat.No. | Name | Information |
|---|---|---|
| M2206 | TH-302 (Evofosfamide) | TH-302 is a highly potent and selective hypoxia-activated procompound targeting hypoxic regions of solid tumors with IC50 of 19 nM. |
| M6098 | Baicalein | Baicalein is a CYP2C9 and prolyl endopeptidase inhibitor, IC50 value of 3.12 mM. |
| M9325 | EGTA | EGTA is a specific calcium chelator with a Kd of 60.5 nM at physiological pH (7.4) and a high specificity for Ca2+ than for Mg2+.EGTA significantly inhibits the substrate adhesion capacity of inflammatory macrophages. |
| M9330 | Brij-35 | Brij-35 (Polidocanol) is a high HLB, ethoxylated, nonionic ether of lauryl alcohol with broad pH stability. |
| M6154 | 2-PMPA tetrasodium | 2-PMPA (PMPA tetrasodium salt) is a potent and selective inhibitor of glutamate carboxypeptidase II (GCPII) with an IC50 of 300 pM. |
| M2250 | Pamidronate disodium | Pamidronate disodium is a nitrogen containing bisphosphonate, used to the research of preventing osteoporosis. |
| M9916 | DPPH | DPPH (2,2-Diphenyl-1-picrylhydrazyl) is a stable free radical that measures the free radical scavenging activity of antioxidants. |
| M9194 | Insulin (human) | Insulin (human) is a polypeptide hormone that regulates the level of sugar (glucose) in the blood and is produced by beta cells of islets. |
| M3409 | Formestane | Formestane is a second generation selective aromatase inhibitor with an IC50 of 80 nM. |
| M9665 | N-(2-amino-2-oxoethyl)acrylamide | N-(2-Amino-2-oxoethyl)acrylamide |
| M24874 | Imaprelimab | Imaprelimab (PRX-003) is a humanized IgG1κ anti-melanoma cell adhesion molecule (MCAM) monoclonal antibody. Imaprelimab is an antineoplastic agent. |
| M24863 | Bifikafusp alfa | Bifikafusp alfa (L19-IL2) is an immunotherapy fusion protein consisting of human L19 antibodies fused to the human cytokine interleukin 2 (IL2).Bifikafusp alfa is specific to the EDB domain of fibronectin. Bifikafusp alfa has anticancer activity. |
| M24861 | Anetumab | Anetumab (Anti-MSLN Antibody) is an anti-mesothelin (MSLN) antibody. MSLN is a tumor-associated antigen. Anetumab can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC). Anetumab can be used for the research of malignant tumor. |
| M24860 | Minretumomab | Minretumomab (CC-49) is a mouse anti-TAG-72 (tumor-associated glycoprotein 72) monoclonal antibody and a radioimmunoconjugate. Minretumomab can be used for the research of cancer and radioimmunotherapy (RIT). |
| M24859 | Vepalimomab | Vepalimomab (Anti-Human AOC3 Recombinant Antibody) is a monoclonal antibody that blocks vascular adhesion protein 1 (VAP-1). Vepalimomab has anti-inflammatory effects. |
| M24857 | Berlimatoxumab | Berlimatoxumab (ASN-2) is an antibody. Berlimatoxumab can be used for experiment research. |
| M24856 | Atidortoxumab | Atidortoxumab is a human IgG1κ monoclonal antibody that targets Staph aureus alpha toxin. |
| M24854 | Ianalumab | Ianalumab (VAY-736) is a humanized, decarboxylated antibody against BAFF-R. Ianalumab can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF. Ianalumab exerts antibody-dependent cytotoxic (ADCC), depending on effector cell activation mediated by immune receptor tyrosine activation motif (ITAM). |
| M24844 | Omburtamab | Omburtamab is an anti-CD276 (also known as B7-H3) monoclonal antibody, CD276 is a B7/CD28 immunoglobulin superfamily member expressed among solid human tumours. Omburtamab can bind tumor tissues and be used in various cancers research. |
| M24838 | Loncastuximab | Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL). |
| M24836 | Pegacaristim | Pegacaristim is a monoclonal antibody with thrombopoietic activity. Pegacaristim can promote generation of platelets. |
| M24833 | Cibisatamab | Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research. |
| M24829 | Clenoliximab | Clenoliximab (IDEC-151) is a macaque-human chimeric monoclonal antibody (immunoglobulin G4) specific for the CD4 molecule on the surface of T lymphocytes. Clenoliximab can be used for the research of rheumatoid arthritis. |
| M24826 | Azintuxizumab | Azintuxizumab is a monoclonal, B-cell maturation antigen (BCMA)-targeted, IgG4 bispecific antibody. Azintuxizumab has the potential for the research of relapsed/refractory multiple myeloma (RRMM). |
| M24825 | Gatralimab | Gatralimab (GZ-402668) is an IgG1 anti-CD52 monoclonal antibody. |
| M24822 | Tisagenlecleucel | Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma. |
| M24819 | Nonacog alfa | Nonacog alfa (BAX326) is a recombinant human factor IX that can be used for the research of haemophilia B. |
| M24815 | Efgivanermin alfa | Efgivanermin alfa is an active peptide. Efgivanermin alfa can be used for various biochemical studies. |
| M24813 | Oleclumab | Oleclumab (MEDI9447) is a human IgG1λ anti-CD73 monoclonal antibody that inhibits CD73 function. Oleclumab has an anti-tumor activity. |
| M24810 | Eftilagimod alfa | Eftilagimod alfa (IMP321) is a recombinant LAG-3Ig fusion protein that binds to MHC class II. Eftilagimod alfa mediates antigen-presenting cell (APC) activation followed by CD8 T-cell activation. Eftilagimod alfa can be used for metastatic melanoma and metastatic breast carcinoma research. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
